FDA approves Eliquis (apixaban) for treatment of DVT and PE
Bristol-Myers Squibb and Pfizer announced the FDA has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE. August 21, 2014